Quest Expands in Cancer Testing With $300M Haystack Oncology Acquisition
Quest Diagnostics is acquiring liquid biopsy company Haystack Oncology. The startup’s technology is used for identifying cancer patients who need adjuvant therapy.
Quest Diagnostics is acquiring liquid biopsy company Haystack Oncology. The startup’s technology is used for identifying cancer patients who need adjuvant therapy.
The tests could prove useful in screening patients that coud benefit from therapies being tested for Alzheimer's. But uptake will depend, in part, on reimbursement, according to doctors surveyed by Quest.
Walmart's partnership with Health at Scale is meant to connect employees and their families with health providers who can best care for them. The retail giant's collaboration with Quest Diagnostics is aimed at increasing consumer access to high-quality lab tests.
After insurers were mandated to cover at-home Covid-19 tests, more people tested at-home screenings for other conditions, speakers said in a discussion hosted by MedCity INVEST. As preventive tests declined significantly during the pandemic, insurers also turned to creative means to give people access.
IQVIA has acquired Quest Diagnostics’ minority stake in Q2 Solutions, a central laboratory services joint venture the two companies formed in 2015. But Quest will remain a preferred provider of lab testing services under an agreement with Q2.
While all these companies have been involved in developing testing, vaccines and drugs for SARS-CoV-2, fears related to the global coronavirus pandemic have taken their toll on them as well as firms in other sectors.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The lab testing company made the announcement as the virus has rapidly spread across the world, and the administration's response has received widespread criticism. LabCorp also announced the availability of its test.
The companies said the deal, financial terms of which were not disclosed, would enable expansion of next-generation sequencing capabilities in rare diseases.
AMCA has told LabCorp that it is in the process of sending notices to the approximately 200,000 of the company's consumers whose credit card or bank account information may have been accessed and will offer them identity protection and credit monitoring services for 24 months.
Quest Diagnostics was notified by collections company vendor American Medical Collection Agency that an unauthorized user had access had access to AMCA’s system between August 1, 2018 and March 30, 2019.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The new tools build on the company's Azure cloud platform and allow more efficient and secure communication and sharing of personal health information.
Keeping health plan provider directories current is a major administrative and cost burden for the industry, with an estimated $2.1 billion spent annually across the healthcare system to acquire and maintain provider data.
Five healthcare organizations — Humana, UnitedHealthcare, Optum, Quest Diagnostics and MultiPlan — have unveiled a blockchain-based effort that aims to make it easier to share provider directory data.
In addition to the acquisition, Quest Diagnostics and the Cleveland Clinic have embarked on a strategic collaboration that will evaluate biomarkers for various diseases, with Quest developing tests for some of them.
What does the future of value-based care look like, and how does technology tie in? A new survey from Quest Diagnostics and Inovalon takes a closer look.